复方苦参注射液防治原发性肝癌复发转移的临床效果

Effects of Compound Kushen Injection in Prevention and Treatment of Recurrence and Metastasis of Primary Hepatic Cellular Carcinoma and the Effect on Serum P53 Antibody,VEGF,TGF-β1 and Ki67 levels

目的:研究复方苦参注射液防治原发性肝癌(HCC)复发转移的效果并探究其对血清P53抗体、血管内皮生长因子(VEGF)、转化生长因子-β_1(TGF-β_1)及Ki67表达的影响。方法:选取2014年7月至2016年7月唐山市人民医院收治的原发性肝癌患者72例,根据入院顺序编号采取随机数表法将患者分为2组,每组36例,对照组给予单纯化疗治疗,观察组在对照组治疗基础上联合复方苦参注射液治疗,比较2组患者临床疗效及治疗安全性。结果:观察组患者总有效率为47.22%显著高于对照组的25.00%(P<0.05);治疗后观察组CD3^+、CD4^+、CD4^+/CD8^+水平分别为(58.15±9.25)%、(44.41±5.63)%、1.71±0.56高于对照组的(51.14±6.54)%、(32.66±4.29)%、1.06±0.26(P<0.05);观察组患者血清P53抗体、VEGF、TGF-β_1及Ki67水平分别为(153.29±31.85)pg/m L、(214.39±31.28)pg/m L、(16.47±1.93)ng/m L、(71.34±6.27)%低于对照组的(189.94±44.21)pg/m L、(352.87±43.67)pg/m L、(25.63±4.26)ng/m L、(82.37±7.12)%(P<0.05);观察组患者发热、骨髓抑制发生率分别为5.56%、2.78%,低于照组的27.78%、36.11%(P<0.05)。结论:复方苦参注射液联合化疗治疗能通过降低血清标志物水平、诱导癌细胞凋亡杀灭癌细胞,有效防治HCC复发转移的发生,且临床不良反应发生率低。

Objective： To study the effects of compound Kushen injection in prevention and treatment of primary hepatic cellular carcinoma（ HCC） and the effect on serum P53 antibody,vascular endothelial growth factor（ VEGF）,transforming growth factorβ1（ TGF-β1） and Ki67 levels. Methods： A total of 72 patients with primary HCC who were admitted to our hospital between July2014 and July 2016 were randomly divided into two groups according to the order of admission,with 36 cases in each group. The control group was treated with chemotherapy alone,while the observation group was treated with compound Kushen injection on the basis of the control group. The clinical efficacy and safety were compared between the two groups. Results： The total effective rate of treatment was significantly higher in the observation group than the control group（ 47. 22% vs 25. 00%）（ P〈 0. 05）. After treatment,the levels of CD3,CD4 and CD4/CD8 in the observation group [（ 58. 15 ± 9. 25） %,（ 44. 41 ± 5. 63） %,（ 1. 71 ±0. 56） ] were significantly higher than those in the control group[（ 51. 14 ± 6. 54） %,（ 32. 66 ± 4. 29） %,（ 1. 06 ± 0. 26） ]（ P 〈0. 05）. The levels of serum P53 antibody,VEGF,TGF-β1 and Ki67 in the observation group [（ 153. 29 ± 31. 85） pg/m L,（ 214. 39 ± 31. 28） pg/m L,（ 16. 47 ± 1. 93） ng/m L,（ 71. 34 ± 6. 27） %]were significantly lower than those in the control group[（ 189. 94 ± 44. 21） pg/m L,（ 352. 87 ± 43. 67） pg/m L,（ 25. 63 ± 4. 26） ng/m L,（ 82. 37 ± 7. 12） % ]（ P〈 0. 05）. The incidence rates of fever and bone marrow suppression in the observation group（ 5. 56%,2. 78%） were significantly lower than those in the control group（ 27. 78%,36. 11%）（ P〈 0. 05）. Conclusion： Compound Kushen injection combined with chemotherapy can effectively control recurrence and metastasis of HCC by reducing the levels of serum markers and inducing cancer cell withering. The incidence of clinical adverse reactions is low.